Cite
HARVARD Citation
Bendell, J. et al. (n.d.). LBA-004Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Annals of oncology. p. . [Online].